1. Home
  2. ANVS vs LUNG Comparison

ANVS vs LUNG Comparison

Compare ANVS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

HOLD

Current Price

$2.24

Market Cap

69.1M

Sector

Health Care

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.57

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANVS
LUNG
Founded
2008
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.1M
57.9M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
ANVS
LUNG
Price
$2.24
$1.57
Analyst Decision
Strong Buy
Buy
Analyst Count
2
7
Target Price
$13.50
$5.38
AVG Volume (30 Days)
1.1M
520.2K
Earning Date
05-12-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
39.39
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$1.54
$1.13
52 Week High
$5.50
$3.88

Technical Indicators

Market Signals
Indicator
ANVS
LUNG
Relative Strength Index (RSI) 55.41 66.44
Support Level $1.92 $1.51
Resistance Level $2.38 $1.64
Average True Range (ATR) 0.17 0.09
MACD 0.00 0.04
Stochastic Oscillator 69.40 82.34

Price Performance

Historical Comparison
ANVS
LUNG

About ANVS Annovis Bio Inc.

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: